Interim Report Archives

Xspray Pharma publishes Interim Report Q3, January – September 2019

Significant events during the third quarter 2019 • Xspray announced that the company aims to up-list to Nasdaq Stockholm in the first half of 2020 • The commercial manufacturing process of amorphous material on a commercial scale with Xspray’s patented technology has been validated and tested for robustness by the company’s Italian manufacturing partner Significant […]

Xspray Pharma publishes Interim Report Q2, January – June 2019

August 29, 2019 ”We have previously shown that it is possible to manufacture small pilot quantities of amorphous material for clinical studies but now we have shown that the process works at commercial scale. We have ”cracked the code”, so to speak, and have taken a great step toward a finished product.” Per Andersson, CEO […]

Xspray Pharma publishes Interim Report Q1, January-March 2019

May 16, 2019 ”Over the past year, we’ve tripled the number of employees and I’m very pleased to see that our entire team is performing high quality work with great commitment. Xspray is today a company well-equipped to take a drug all the way to a finished product.” Per Andersson, CEO Xspray Pharma AB (publ) […]